Zattarin, Emma
Presti, Daniele
Mariani, Luigi http://orcid.org/0000-0001-6208-4084
Sposetti, Caterina http://orcid.org/0000-0003-3211-8516
Leporati, Rita http://orcid.org/0000-0001-6671-9809
Menichetti, Alice
Corti, Chiara http://orcid.org/0000-0002-0359-0267
Benvenuti, Chiara
FucĂ , Giovanni http://orcid.org/0000-0002-1560-2253
Lobefaro, Riccardo
Ligorio, Francesca
Provenzano, Leonardo
Vingiani, Andrea
Del Vecchio, Marta
Griguolo, Gaia http://orcid.org/0000-0002-8782-4509
Sirico, Marianna
Bernocchi, Ottavia
Marra, Antonio http://orcid.org/0000-0002-7310-7824
Zagami, Paola
Agostinetto, Elisa http://orcid.org/0000-0003-0295-7511
Jacobs, Flavia
Di Mauro, Pierluigi http://orcid.org/0000-0002-1975-0923
Esposito, Andrea
Giorgi, Carlo Alberto http://orcid.org/0000-0001-5406-0357
Lalli, Luca
Boldrini, Laura
Giacchetti, Pier Paolo Berton http://orcid.org/0000-0001-5559-7279
Schianca, Ambra Carnevale
Guarneri, Valentina http://orcid.org/0000-0002-2375-8397
Pedersini, Rebecca
Losurdo, Agnese
Zambelli, Alberto
Generali, Daniele
Criscitiello, Carmen
Curigliano, Giuseppe http://orcid.org/0000-0003-1781-2518
Pruneri, Giancarlo http://orcid.org/0000-0002-7963-7172
de Braud, Filippo
Dieci, Maria Vittoria
Vernieri, Claudio http://orcid.org/0000-0003-1577-8176
Article History
Received: 16 December 2022
Accepted: 4 April 2023
First Online: 17 April 2023
Competing interests
: G.G. reports personal fees from Novartis, Eli Lilly. E.A. reports consultancy fees or honoraria from Eli Lilly, Sandoz; support to attend medical conferences from Roche, Novartis, Eli Lilly, Genetic, Istituto Gentili. V.G. reports personal fees from Eli Lilly, Novartis, Roche, and MSD outside the submitted work. D.G. reports consultancy fees or honoraria from Eli Lilly, Novartis, Pfizer, Roche, Istituto Gentili, Eisai. G.C. reports funding from Astra Zeneca, Daichii Sankyo, Merck; consulting fees from BMS, Roche, Pfizer, Novartis, Lilly, Astra Zeneca, Daichii Sankyo, Merck, Seagen, Ellipsis; honoraria from Pfizer, Lilly; support for attending meetings from Roche, Pfizer. G.P. reports personal fees from Roche Foundation One, Bayer, Novartis, and personal fees from Lilly outside the submitted work. F.d.B. reports an advisory role at Roche, EMD Serono, NMS Nerviano Medical Science, Sanofi, MSD, Novartis, Incyte, BMS, Menarini; speaker role for BMS, Healthcare Research & Pharmacoepidemiology, Merck Group, ACCMED, Nadirex, MSD, Pfizer, Servier, Sanofi, Roche, AMGEN, Incyte, Dephaforum; Principal Investigator for Novartis, F.Hoffmann-LaRoche Ltd, BMS, Ignyta Operating INC, Merck Sharp & Dohme Spa, Kymab, Pfizer, Tesaro, MSD, MedImmune LCC, Exelixis Inc., LOXO Oncology Incorporated, DAICHI SANKIO Dev. Limited, Basilea Pharmaceutica International AG, Janssen-Cilag International NV, Merck KGAA. M.V.D. reports personal fees from Eli Lilly, MSD, Exact Sciences, Novartis, Pfizer, Seagen, C.V. reports an advisory role for Novartis, Pfizer and Daiichi Sankyo; honoraria as a speaker: Lilly, Novartis, Istituto Gentili; research grants: Roche. All other authors report no competing interests.